Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Off-Label Communications Bill Allowing Discussion Of Unapproved Drugs Advances

Executive Summary

Safe harbor for off label discussions between manufacturers and payers clears US House Energy & Commerce Health Subcommittee. Bill covers unapproved drugs as well as off label uses for approved agents.

You may also be interested in...



Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill

By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

‘Better informed patients,’ ‘drug competition,’  ‘biosimilar innovation’ as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

‘Better informed patients,’ ‘drug competition,’  ‘biosimilar innovation’ as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel